Briefly, here we present the synthesis of a novel polysaccharide prodrug, MR-5FU functionalised AuNcg formulation, with a targeting monoclonal antibody, an anti-CD133 antibody, for the treatment of glioblastoma. Here, PROM1 is linked to glioblastoma.